📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. (2018)

First Author: Seelig E

Attributed to: Adaptive Clinical Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1172/jci.insight.99306

PubMed Identifier: 30282826

Publication URI: http://europepmc.org/abstract/MED/30282826

Type: Journal Article/Review

Volume: 3

Parent Publication: JCI insight

Issue: 19

ISSN: 2379-3708